P. Langley

D. W. Hawkins, P. Langley, K. Krueger, 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

The Everyday Life of Global Finance: Saving and Borrowing in Anglo-America

P. Langley, 2008 .

More Unnecessary Imaginary Worlds – Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease

P. Langley, 2020, Innovations in pharmacy.

More Unnecessary Imaginary Worlds – Part 3: Cystic Fibrosis and the Institute for Clinical and Economic Review’s Draft Evidence Report

P. Langley, 2020, Innovations in pharmacy.

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis

P. Langley, 2020, Innovations in pharmacy.

Imaginary Worlds: A Systematic Review of the Status of Modeled Cost-Effectiveness Claims Published in the Journal of Medical Economics from January 2015 to December 2015

P. Langley, T. G. Rhee, 2017 .

Cost-effectiveness of regional poison control centers.

P. Langley, J. Draugalis, M. Slack, 1996, Archives of internal medicine.

Antioxidant and Associated Capacities of Camu Camu (Myrciaria dubia): A Systematic Review

P. Langley, J. Pergolizzi, C. Ridgway, 2015, Journal of alternative and complementary medicine.

Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure

P. Langley, S. McKenna, 2021, Innovations in pharmacy.

Dreamtime: Version 5.0 of the Australian Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC)

Paul C Langley, P. Langley, 2017 .

The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan.

G. L’italien, P. Langley, M. Dibonaventura, 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A cost-effectiveness analysis of sinecatechins in the treatment of external genital warts

P. Langley, 2010, Journal of medical economics.

Power knowledge estranged: from Susan Strange to poststructuralism in British IPE

P. Langley, 2009 .

The impact of rheumatoid arthritis on the burden of disease in urban China

P. Langley, R. Mu, Michael Wu, 2011, Journal of medical economics.

Adequacy of health-related quality of life measures in children under 5 years old: systematic review.

P. Langley, H. Bekker, J. Noyes, 2007, Journal of advanced nursing.

A review of cost-of-illness studies on obesity.

P. Langley, E. Cox, M. Kortt, 1998, Clinical therapeutics.

The burden associated with neuropathic pain in Western Europe

P. Langley, J. Cappelleri, D. Carroll, 2013, Journal of medical economics.

Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with CHEERS 22

P. Langley, 2022, F1000Research.

Fundamental Outcome Measurement: Selecting Patient Reported Outcome Instruments and Interpreting the Data they Produce

P. Langley, S. McKenna, A. Heaney, 2021, Innovations in pharmacy.

Measurement, modeling and QALYs

Stephen P. McKenna, Paul C. Langley, P. Langley, 2020, F1000Research.

Measurement, modeling and QALYs [version 1; peer review: awaiting peer review]

P. Langley, S. McKenna, 2020 .

Humanistic and economic impacts of hepatitis C infection in the United States

G. L’italien, P. Langley, M. Dibonaventura, 2010, Journal of medical economics.

The Great I-QALY Disaster

P. Langley, 2020, Innovations in pharmacy.

Establishing Credibility for Medical Marijuana: The Proposed Prometheus Dispensary Registry for Botanical Cannabis

P. Langley, 2019, Innovations in pharmacy.

The societal burden of pain in Germany: Health-related quality-of-life, health status and direct medical costs

P. Langley, 2012, Journal of medical economics.

P. Langley, Concepción Pérez Hernández, César Margarit Ferrí, 2011, Journal of medical economics.

The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes

G. L’italien, P. Langley, Yong Yuan, 2012, European journal of gastroenterology & hepatology.

The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities

G. L’italien, P. Langley, M. Dibonaventura, 2011, Journal of medical economics.

The Imaginary Worlds of ISPOR: Modeled Cost-Effectiveness Claims Published in Value in Health from January 2016 to December 2016

P. Langley, T. G. Rhee, 2017 .

Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds.

P. Langley, 2018, Innovations in pharmacy.

Resolving Lingering Problems or Continued Support for Pseudoscience? The ICER Value Assessment Update

P. Langley, 2017 .

More Imaginary Worlds: A Systematic Review of the Status of Modeled Cost-Effectiveness Claims Published in the Journal of Medical Economics from January 2016 to December 2016

P. Langley, T. G. Rhee, T. Rhee, 2017 .

Imaginary Worlds and the Institute for Clinical and Economic Review (ICER) Evidence Report: Targeted Immune Modulators for Rheumatoid Arthritis

P. Langley, 2017 .

True North: Building Imaginary Worlds with the Revised Canadian (CADTH) Guidelines for Health Technology Assessment

P. Langley, 2017 .

Multiple Sclerosis and the Comparative Value Disease Modifying Therapy Report of the Institute for Clinical and Economic Review (ICER)

P. Langley, 2017 .

Imaginary Worlds: The Status of Modeled Economic Evaluation Claims Published in Value in Health January 2015 to December 2015

P. Langley, T. G. Rhee, 2016 .

Imaginary Worlds: Modeled claims for cost-effectiveness published in PharmacoEconomics January 2015 to December 2015

P. Langley, 2016 .

Disease management programs.

P. Langley, E. Armstrong, 1996, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Is cost effectiveness modeling useful?

P. Langley, 2000, The American journal of managed care.

A Utility Assessment of Oral and Intravenous Ganciclovir for the Maintenance Treatment of AIDS-Related Cytomegalovirus Retinitis

P. Langley, S. Sullivan, Eric S. Johnson, 1996, PharmacoEconomics.

A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.

D. W. Hawkins, P. Langley, K. Krueger, 1998, Clinical therapeutics.

A retrospective analysis of costs and patterns of treatment for external genital warts in The Netherlands.

P. Langley, W. I. van der Meijden, F. Blog, 2002, Clinical therapeutics.

Where Ignorance Is Bliss: The Institute for Clinical and Economic Review (ICER), The University of Washington, College of Pharmacy CHOICE Institute and Simulation Pricing and Access Recommendations for Atopic Dermatitis

P. Langley, 2021, INNOVATIONS in pharmacy.

A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis

P. Langley, 2021, Innovations in pharmacy.

Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis

P. Langley, D. Veenstra, M. Higashi, 2004, PharmacoEconomics.

Establishing Practice Risk Management and Outcomes Claims for Medical Marijuana Dispensaries: Questions Legislators Should Ask

P. Langley, 2019, Innovations in pharmacy.

The association of pain with labor force participation, absenteeism, and presenteeism in Spain

P. Langley, C. Ferrí, Jesús Tornero Molina, 2011, Journal of medical economics.

Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment

P. Langley, 2021, Innovations in pharmacy.

Fundamental Measurement and Quality-Adjusted Life Years.

Paul C Langley, Stephen P McKenna, P. Langley, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement

P. Langley, 2020, Innovations in pharmacy.

The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalers.

P. Langley, 1999, Clinical therapeutics.

A Practice Based Behavioral Health Management Registry (BHMR): Implementation, Structure and Content

P. Langley, 2019, Innovations in pharmacy.

Meeting Physician Compliance Recommendations in the Management of Opioids in Chronic Pain: The Chronic Pain Management Registry (CPMR)

P. Langley, 2019, Innovations in pharmacy.

A Practice Based Chronic Pain Management Registry (CPMR): Structure and Content of Proposed Patient and Patient/Provider Platforms

P. Langley, 2019, Innovations in pharmacy.

Outcomes, Registries and Medical Marijuana: Towards Establishing Dispensary Monitoring and Reporting Standards

P. Langley, 2018, Innovations in pharmacy.